Skip to search formSkip to main contentSkip to account menu

RC 3095

Known as: RC-3095 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis.
OBJECTIVE To evaluate the antiinflammatory effects of RC-3095 in 2 experimental models of arthritis, collagen-induced arthritis… 
2007
2007
Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: Implications for an animal model of neurodevelopmental disorders
Highly Cited
1997
Highly Cited
1997
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
Epidermal growth factor (EGF) and its receptors (EGFR) play important roles in tumorigenesis. In various experimental cancers… 
Highly Cited
1994
Highly Cited
1994
Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin analogue RC‐160
Nude mice bearing xenografts of the gastrin‐responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with… 
Highly Cited
1993
Highly Cited
1993
Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice
Nude mice bearing xenografts of the androgen‐independent human prostate‐cancer cell line PC‐3 were treated for 4 weeks with… 
Highly Cited
1992
Highly Cited
1992
Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines.
Recently, it was reported that bombesin/gastrin-releasing peptide (GRP) have mitogenic effects on some human breast cancer cell… 
Highly Cited
1992
Highly Cited
1992
Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and…
The effects of treatment with a bombesin receptor antagonist [D‐Tpi6, Leu13Ψ(CH2NH) Leu14]BN(6–14)(RC‐3095) and the combination… 
Highly Cited
1992
Highly Cited
1992
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
BACKGROUND Many breast cancers are estrogen independent, and even in patients who initially respond to estrogen suppression… 
Highly Cited
1991
Highly Cited
1991
Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with a [D-Trp6] agonist of… 
Highly Cited
1991
Highly Cited
1991
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Female Syrian golden hamsters with N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancers were treated for 2 months with new… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)